Eli Lilly Launches Open Letter about Mounjaro® and Zepbound® Use
Lilly's Open Letter on Tirzepatide Medicines: Mounjaro and Zepbound should not be used for cosmetic weight loss. Patient safety is top priority.
7939 NW 21st St
Miami, Florida
Lilly's Open Letter on Tirzepatide Medicines: Mounjaro and Zepbound should not be used for cosmetic weight loss. Patient safety is top priority.
Jim Cramer discusses Walmart's stock split, Berkshire Hathaway's underperformance, Domino's strong results, and Zealand Pharma's promising drug trial.
New diabetes drug Zepbound, also known as tirzepatide, can be sold as a weight-loss drug, helping dieters lose 40-60 pounds.